JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasama, S.
Right arrow Articles by Kurabayashi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasama, S.
Right arrow Articles by Kurabayashi, M.
Journal of Nuclear Medicine Vol. 44 No. 6 884-890
© 2003 by Society of Nuclear Medicine


Clinical Investigations

Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure

Shu Kasama, MD1, Takuji Toyama, MD1, Hisao Kumakura, MD2, Yoshiaki Takayama, MD2, Shuichi Ichikawa, MD2, Tadashi Suzuki, MD1 and Masahiko Kurabayashi, MD1

1 Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan
2 Cardiovascular Hospital of Central Japan, Gunma, Japan

We determined whether the addition of the angiotensin-receptor blocker valsartan to an angiotensin-converting enzyme (ACE) inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure (CHF). Methods: Thirty-two patients with CHF (left ventricular ejection fraction [LVEF] < 40%; mean, 33% ± 6%) were treated with an ACE inhibitor and a loop diuretic. Sixteen patients (group A) were randomized to additionally receive valsartan (40–80 mg/d), and the remaining 16 patients (group B) continued their current regimen. Patients were studied before and 6 mo after treatment. The delayed heart-to-mediastinum count ratio (H/M ratio), delayed total defect score (TDS), and washout rate (WR) were determined from 123I-metaiodobenzylguanidine images. The left ventricular end-diastolic volume (LVEDV) and LVEF were determined by echocardiography, and New York Heart Association (NYHA) functional class was estimated. Results: Before treatment, TDS, H/M ratio, WR, LVEDV, LVEF, and NYHA functional class were similar in both groups. After treatment in group A, TDS decreased from 37 ± 8 to 31 ± 9 (P < 0.001), H/M ratio increased from 1.66 ± 0.23 to 1.81 ± 0.23 (P < 0.001), and WR decreased from 47% ± 9% to 39% ± 10% (P < 0.01). In addition, the LVEDV decreased from 193 ± 36 mL to 169 ± 51 mL (P < 0.005), and LVEF increased from 32% ± 7% to 41% ± 13% (P = 0.0005). In group B, these parameters did not change significantly. NYHA functional class improved in both groups (in group A, from 3.3 ± 0.5 to 1.7 ± 0.6 [P < 0.0005]; in group B, from 3.3 ± 0.5 to 2.4 ± 0.6; [P < 0.005]). The improvement was significantly greater in group A than in group B (P < 0.05). Conclusion: The addition of valsartan to an ACE inhibitor improves cardiac sympathetic nerve activity, left ventricular function, and symptoms in patients with CHF.

Key Words: 123I-metaiodobenzylguanidine • heart failure • angiotensin-receptor blocker




This article has been cited by other articles:


Home page
JNMHome page
S. Kasama, T. Toyama, H. Sumino, M. Nakazawa, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, et al.
Prognostic Value of Serial Cardiac 123I-MIBG Imaging in Patients with Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction
J. Nucl. Med., June 1, 2008; 49(6): 907 - 914.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. Nagahara, T. Nakata, A. Hashimoto, T. Wakabayashi, M. Kyuma, R. Noda, S. Shimoshige, K. Uno, K. Tsuchihashi, and K. Shimamoto
Predicting the Need for an Implantable Cardioverter Defibrillator Using Cardiac Metaiodobenzylguanidine Activity Together with Plasma Natriuretic Peptide Concentration or Left Ventricular Function
J. Nucl. Med., February 1, 2008; 49(2): 225 - 233.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. Kasama, T. Toyama, H. Sumino, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure
J. Nucl. Med., December 1, 2007; 48(12): 1993 - 2000.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials
Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. Kasama, T. Toyama, H. Sumino, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Long-Term Nicorandil Therapy Improves Cardiac Sympathetic Nerve Activity After Reperfusion Therapy in Patients with First Acute Myocardial Infarction
J. Nucl. Med., October 1, 2007; 48(10): 1676 - 1682.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. A. Gould, G. Kong, V. Kalff, S. J. Duffy, A. J. Taylor, M. J. Kelly, and D. M. Kaye
Improvement in cardiac adrenergic function post biventricular pacing for heart failure
Europace, September 1, 2007; 9(9): 751 - 756.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kasama, T. Toyama, T. Hatori, H. Sumino, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Effects of Intravenous Atrial Natriuretic Peptide on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients With First Anterior Acute Myocardial Infarction
J. Am. Coll. Cardiol., February 13, 2007; 49(6): 667 - 674.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi
Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure
Heart, October 1, 2006; 92(10): 1434 - 1440.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure
Heart, May 1, 2006; 92(5): 625 - 630.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. B. Davidson, J. K. Hix, D. G. Vidt, and D. J. Brotman
Association of Impaired Diurnal Blood Pressure Variation With a Subsequent Decline in Glomerular Filtration Rate.
Arch Intern Med, April 24, 2006; 166(8): 846 - 852.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction
J. Am. Coll. Cardiol., March 1, 2005; 45(5): 661 - 667.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, S. Tange, T. Suzuki, and M. Kurabayashi
Dobutamine Stress 99mTc-Tetrofosmin Quantitative Gated SPECT Predicts Improvement of Cardiac Function After Carvedilol Treatment in Patients with Dilated Cardiomyopathy
J. Nucl. Med., November 1, 2004; 45(11): 1878 - 1884.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, T. Ishikawa, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Effects of Intravenous Atrial Natriuretic Peptide on Cardiac Sympathetic Nerve Activity in Patients with Decompensated Congestive Heart Failure
J. Nucl. Med., July 1, 2004; 45(7): 1108 - 1113.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.